JP2014240408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014240408A5 JP2014240408A5 JP2014158170A JP2014158170A JP2014240408A5 JP 2014240408 A5 JP2014240408 A5 JP 2014240408A5 JP 2014158170 A JP2014158170 A JP 2014158170A JP 2014158170 A JP2014158170 A JP 2014158170A JP 2014240408 A5 JP2014240408 A5 JP 2014240408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- eosinophilic
- prednisone
- treatment
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4036308P | 2008-03-28 | 2008-03-28 | |
| US61/040,363 | 2008-03-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502090A Division JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016214438A Division JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014240408A JP2014240408A (ja) | 2014-12-25 |
| JP2014240408A5 true JP2014240408A5 (enExample) | 2016-02-18 |
| JP6069267B2 JP6069267B2 (ja) | 2017-02-01 |
Family
ID=41114741
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502090A Active JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
| JP2014158170A Active JP6069267B2 (ja) | 2008-03-28 | 2014-08-01 | 処置方法 |
| JP2016214438A Active JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
| JP2018238018A Pending JP2019065029A (ja) | 2008-03-28 | 2018-12-20 | 処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502090A Active JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016214438A Active JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
| JP2018238018A Pending JP2019065029A (ja) | 2008-03-28 | 2018-12-20 | 処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9834600B2 (enExample) |
| EP (1) | EP2274009B1 (enExample) |
| JP (4) | JP5917143B2 (enExample) |
| KR (1) | KR20100134702A (enExample) |
| CN (1) | CN102026660A (enExample) |
| AU (1) | AU2009228163B2 (enExample) |
| BR (1) | BRPI0910854A2 (enExample) |
| CA (1) | CA2719786A1 (enExample) |
| EA (1) | EA201071137A1 (enExample) |
| ES (1) | ES2441945T3 (enExample) |
| IL (1) | IL208354A0 (enExample) |
| MX (1) | MX2010010667A (enExample) |
| WO (1) | WO2009120927A2 (enExample) |
| ZA (1) | ZA201006648B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101715443A (zh) | 2007-03-14 | 2010-05-26 | 诺普神经科学股份有限公司 | 手性纯化的取代的苯并噻唑二胺的合成 |
| JP5917143B2 (ja) | 2008-03-28 | 2016-05-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 処置方法 |
| US20110190356A1 (en) | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| ES3043076T3 (en) | 2013-07-12 | 2025-11-24 | Areteia Therapeutics Inc | Treating elevated levels of eosinophils and/or basophils |
| ES2871556T3 (es) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de la urticaria crónica |
| WO2015023786A1 (en) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| DK3191513T3 (da) | 2014-09-08 | 2020-08-24 | Cephalon Inc | Anvendelse af reslizumab til behandling af moderat til svær eosinofil astma |
| CN116327922A (zh) * | 2015-08-24 | 2023-06-27 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 生物医药组合物 |
| WO2018215964A1 (en) | 2017-05-26 | 2018-11-29 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and related methods |
| CA3186844A1 (en) * | 2020-08-05 | 2022-02-10 | Calman Philip PRUSSIN | Use of dexpramipexole for the treatment of moderate to severe asthma |
| WO2026053108A1 (en) * | 2024-09-03 | 2026-03-12 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8800397D0 (en) | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US5096704A (en) | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
| ES2062032T3 (es) | 1988-11-03 | 1994-12-16 | Schering Corp | Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0533006A1 (en) | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
| ES2102007T3 (es) | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. |
| SG49597A1 (en) | 1992-02-06 | 1998-06-15 | Schering Corp | Design cloning and expression of humanized monoclonal antibodies against human interleukin-5 |
| JPH06141885A (ja) | 1992-11-05 | 1994-05-24 | Chemo Sero Therapeut Res Inst | モノクローナル抗体 |
| WO1995014040A1 (en) | 1993-11-19 | 1995-05-26 | Baylor College Of Medicine | Monoclonal antibodies specific for human interleukin-5 |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US7399837B2 (en) | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| ATE346867T1 (de) | 1994-12-23 | 2006-12-15 | Smithkline Beecham Corp | Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten |
| US5683892A (en) | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US5783184A (en) | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
| US6248723B1 (en) | 1997-06-10 | 2001-06-19 | National Jewish Medical And Research Center | Method for treatment of inflammatory disease |
| US20020052390A1 (en) | 1997-10-22 | 2002-05-02 | Jens Ponikau | Methods and materials for treating and preventing inflammation of mucosal tissue |
| WO2001012646A1 (en) | 1999-08-19 | 2001-02-22 | Smithkline Beecham Corporation | Sialoadhesin factor-1 agonist and antagonist antibodies |
| US20030017169A1 (en) | 2000-12-29 | 2003-01-23 | Sidney Pestka | Controlled release systems for polymers |
| ATE435239T1 (de) * | 2002-03-29 | 2009-07-15 | Schering Corp | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen |
| US7339507B1 (en) * | 2006-09-13 | 2008-03-04 | Jiun-In Guo | Device for video decoding |
| EP2097438B1 (en) | 2006-12-11 | 2015-08-26 | Bracco Imaging S.p.A | Fibrin binding peptide conjugates for diagnostic and therapeutic applications |
| JP2010526087A (ja) * | 2007-04-30 | 2010-07-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗ｉｌ−５抗体を投与するための方法 |
| US20090035216A1 (en) | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
| JP5917143B2 (ja) | 2008-03-28 | 2016-05-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 処置方法 |
| US8926631B2 (en) | 2010-08-06 | 2015-01-06 | MoMelan Technologies, Inc. | Methods for preparing a skin graft without culturing or use of biologics |
| DK2672986T3 (da) | 2011-02-09 | 2020-06-08 | Glaxosmithkline Llc | Frysetørrede formuleringer |
-
2009
- 2009-03-27 JP JP2011502090A patent/JP5917143B2/ja active Active
- 2009-03-27 EP EP09725345.4A patent/EP2274009B1/en not_active Revoked
- 2009-03-27 CA CA2719786A patent/CA2719786A1/en not_active Abandoned
- 2009-03-27 WO PCT/US2009/038509 patent/WO2009120927A2/en not_active Ceased
- 2009-03-27 MX MX2010010667A patent/MX2010010667A/es not_active Application Discontinuation
- 2009-03-27 EA EA201071137A patent/EA201071137A1/ru unknown
- 2009-03-27 BR BRPI0910854A patent/BRPI0910854A2/pt not_active IP Right Cessation
- 2009-03-27 KR KR1020107024046A patent/KR20100134702A/ko not_active Withdrawn
- 2009-03-27 ES ES09725345.4T patent/ES2441945T3/es active Active
- 2009-03-27 US US12/935,038 patent/US9834600B2/en active Active
- 2009-03-27 AU AU2009228163A patent/AU2009228163B2/en not_active Ceased
- 2009-03-27 CN CN2009801176573A patent/CN102026660A/zh active Pending
-
2010
- 2010-09-16 ZA ZA2010/06648A patent/ZA201006648B/en unknown
- 2010-09-21 IL IL208354A patent/IL208354A0/en unknown
-
2014
- 2014-08-01 JP JP2014158170A patent/JP6069267B2/ja active Active
-
2016
- 2016-11-01 JP JP2016214438A patent/JP6457463B2/ja active Active
-
2017
- 2017-11-06 US US15/804,104 patent/US20180057582A1/en not_active Abandoned
-
2018
- 2018-12-20 JP JP2018238018A patent/JP2019065029A/ja active Pending
-
2019
- 2019-09-19 US US16/575,903 patent/US11325972B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516422A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2016528247A5 (enExample) | ||
| JP2018184417A5 (enExample) | ||
| EP2433650A3 (en) | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases | |
| JP2018505882A5 (enExample) | ||
| JP2013538553A5 (enExample) | ||
| JP2015007098A5 (enExample) | ||
| JP2013527233A5 (enExample) | ||
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| JP2015534578A5 (enExample) | ||
| JP2017160178A5 (enExample) | ||
| JP2012046518A5 (enExample) | ||
| JP2014530226A5 (enExample) | ||
| JP2016536361A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| PH12018501903A1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| GR1007832B (el) | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" | |
| JP2015505564A5 (enExample) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2018529661A5 (enExample) | ||
| HK1259342A1 (zh) | 用於治疗癌症的联合疗法 | |
| JP2018512402A5 (enExample) | ||
| JP2023534292A5 (enExample) | ||
| WO2018102670A3 (en) | Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down |